Clinical Trials Logo

CDD clinical trials

View clinical trials related to CDD.

Filter by:
  • None
  • Page 1

NCT ID: NCT05558371 Recruiting - Clinical trials for CDKL5 Deficiency Disorder

International CDKL5 Clinical Research Network

ICCRN
Start date: February 15, 2021
Phase:
Study type: Observational

Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease modifying therapies is accelerating, there is a critical barrier for clinical trial readiness that may result in failure of these therapies, not due to lack of efficacy but due to lack of validated outcome measures and biomarkers. The measures and biomarkers validated here will be adaptable to other developmental and epileptic encephalopathies.

NCT ID: NCT03861871 Completed - CDD Clinical Trials

Fenfluramine in CDKL5 Deficiency Disorder (CDD)

Start date: October 29, 2019
Phase: Phase 2
Study type: Interventional

This study will be enrolling 10 patients, ages 2-18 years old, with a confirmed genetic/clinical diagnosis of CDKL5 Deficiency Disorder (CDD) in an open label trial of fenfluramine for seizure control. Patients will be titrated over 14 days to a dose of ZX008 0.8 mg/kg/day (maximum dose 30 mg/d).